WR 151327

Drug Profile

WR 151327

Alternative Names: NSC 327729; NSC 335662

Latest Information Update: 15 Oct 2004

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nonindustrial source; Southern Research Institute
  • Developer MedImmune Oncology; Nonindustrial source
  • Class Antivirals; Radioprotectives
  • Mechanism of Action Oxygen radical scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Chemotherapy-induced damage; HIV infections

Most Recent Events

  • 15 Oct 2004 Discontinued - Preclinical for Chemotherapy induced damage in USA (PO)
  • 15 Oct 2004 Discontinued - Preclinical for HIV infections treatment in USA (unspecified route)
  • 15 Feb 2000 A preclinical study has been added to the Cancer pharmacodynamics and adverse events sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top